The gut microbiome in atherosclerotic cardiovascular disease

Zhuye Jie; Huihua Xia; Shi-Long Zhong; Qiang Feng; Shenghui Li; Suisha Liang; Huanzi Zhong; Zhipeng Liu; Yuan Gao; Hui Zhao; Dongya Zhang; Zheng Su; Zhiwei Fang; Zhou Lan; Junhua Li; Liang Xiao; Jun Li; Ruijun Li; Xiaoping Li; Fei Li; Huahui Ren; Yan Huang; Yangqing Peng; Guanglei Li; Bo Wen; Bo Dong; Ji-Yan Chen; Qing-Shan Geng; Zhi-Wei Zhang; Huanming Yang; Jian Wang; Jun Wang; Xuan Zhang; Lise Madsen; Susanne Brix; Guang Ning; Xun Xu; Xin Liu; Yong Hou; Huijue Jia; Kunlun He; Karsten Kristiansen

doi:10.1038/s41467-017-00900-1

The gut microbiome in atherosclerotic cardiovascular disease

Zhuye Jie, Huihua Xia, Shi-Long Zhong, Qiang Feng, Shenghui Li, Suisha Liang, Huanzi Zhong, Zhipeng Liu, Yuan Gao, Hui Zhao, Dongya Zhang, Zheng Su, Zhiwei Fang, Zhou Lan, Junhua Li, Liang Xiao, Jun Li, Ruijun Li, Xiaoping Li, Fei LiHuahui Ren, Yan Huang, Yangqing Peng, Guanglei Li, Bo Wen, Bo Dong, Ji-Yan Chen, Qing-Shan Geng, Zhi-Wei Zhang, Huanming Yang, Jian Wang, Jun Wang, Xuan Zhang, Lise Madsen, Susanne Brix, Guang Ning, Xun Xu, Xin Liu, Yong Hou, Huijue Jia^*, Kunlun He, Karsten Kristiansen

^*Corresponding author for this work

Genome Research and Molecular Bio Medicine

360 Citations (Scopus)

222 Downloads (Pure)

Abstract

The gut microbiota has been linked to cardiovascular diseases. However, the composition and functional capacity of the gut microbiome in relation to cardiovascular diseases have not been systematically examined. Here, we perform a metagenome-wide association study on stools from 218 individuals with atherosclerotic cardiovascular disease (ACVD) and 187 healthy controls. The ACVD gut microbiome deviates from the healthy status by increased abundance of Enterobacteriaceae and Streptococcus spp. and, functionally, in the potential for metabolism or transport of several molecules important for cardiovascular health. Although drug treatment represents a confounding factor, ACVD status, and not current drug use, is the major distinguishing feature in this cohort. We identify common themes by comparison with gut microbiome data associated with other cardiometabolic diseases (obesity and type 2 diabetes), with liver cirrhosis, and rheumatoid arthritis. Our data represent a comprehensive resource for further investigations on the role of the gut microbiome in promoting or preventing ACVD as well as other related diseases.

Original language	English
Article number	845
Journal	Nature Communications
Volume	8
Issue number	1
Number of pages	12
ISSN	2041-1723
DOIs	https://doi.org/10.1038/s41467-017-00900-1
Publication status	Published - 10 Oct 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41467-017-00900-1Licence: CC BY

Jie_2017_The_gut_microbiomeFinal published version, 3.11 MBLicence: CC BY

Cite this

Jie, Z, Xia, H, Zhong, S-L, Feng, Q, Li, S, Liang, S, Zhong, H, Liu, Z, Gao, Y, Zhao, H, Zhang, D, Su, Z, Fang, Z, Lan, Z, Li, J, Xiao, L, Li, J, Li, R, Li, X, Li, F, Ren, H, Huang, Y, Peng, Y, Li, G, Wen, B, Dong, B, Chen, J-Y, Geng, Q-S, Zhang, Z-W, Yang, H, Wang, J, Wang, J, Zhang, X, Madsen, L, Brix, S, Ning, G, Xu, X, Liu, X, Hou, Y, Jia, H, He, K & Kristiansen, K 2017, 'The gut microbiome in atherosclerotic cardiovascular disease', Nature Communications, vol. 8, no. 1, 845. https://doi.org/10.1038/s41467-017-00900-1

@article{87ea155ddeab458d83071984751690fd,

title = "The gut microbiome in atherosclerotic cardiovascular disease",

abstract = "The gut microbiota has been linked to cardiovascular diseases. However, the composition and functional capacity of the gut microbiome in relation to cardiovascular diseases have not been systematically examined. Here, we perform a metagenome-wide association study on stools from 218 individuals with atherosclerotic cardiovascular disease (ACVD) and 187 healthy controls. The ACVD gut microbiome deviates from the healthy status by increased abundance of Enterobacteriaceae and Streptococcus spp. and, functionally, in the potential for metabolism or transport of several molecules important for cardiovascular health. Although drug treatment represents a confounding factor, ACVD status, and not current drug use, is the major distinguishing feature in this cohort. We identify common themes by comparison with gut microbiome data associated with other cardiometabolic diseases (obesity and type 2 diabetes), with liver cirrhosis, and rheumatoid arthritis. Our data represent a comprehensive resource for further investigations on the role of the gut microbiome in promoting or preventing ACVD as well as other related diseases.",

author = "Zhuye Jie and Huihua Xia and Shi-Long Zhong and Qiang Feng and Shenghui Li and Suisha Liang and Huanzi Zhong and Zhipeng Liu and Yuan Gao and Hui Zhao and Dongya Zhang and Zheng Su and Zhiwei Fang and Zhou Lan and Junhua Li and Liang Xiao and Jun Li and Ruijun Li and Xiaoping Li and Fei Li and Huahui Ren and Yan Huang and Yangqing Peng and Guanglei Li and Bo Wen and Bo Dong and Ji-Yan Chen and Qing-Shan Geng and Zhi-Wei Zhang and Huanming Yang and Jian Wang and Jun Wang and Xuan Zhang and Lise Madsen and Susanne Brix and Guang Ning and Xun Xu and Xin Liu and Yong Hou and Huijue Jia and Kunlun He and Karsten Kristiansen",

year = "2017",

month = oct,

day = "10",

doi = "10.1038/s41467-017-00900-1",

language = "English",

volume = "8",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "nature publishing group",

number = "1",

}

TY - JOUR

T1 - The gut microbiome in atherosclerotic cardiovascular disease

AU - Jie, Zhuye

AU - Xia, Huihua

AU - Zhong, Shi-Long

AU - Feng, Qiang

AU - Li, Shenghui

AU - Liang, Suisha

AU - Zhong, Huanzi

AU - Liu, Zhipeng

AU - Gao, Yuan

AU - Zhao, Hui

AU - Zhang, Dongya

AU - Su, Zheng

AU - Fang, Zhiwei

AU - Lan, Zhou

AU - Li, Junhua

AU - Xiao, Liang

AU - Li, Jun

AU - Li, Ruijun

AU - Li, Xiaoping

AU - Li, Fei

AU - Ren, Huahui

AU - Huang, Yan

AU - Peng, Yangqing

AU - Li, Guanglei

AU - Wen, Bo

AU - Dong, Bo

AU - Chen, Ji-Yan

AU - Geng, Qing-Shan

AU - Zhang, Zhi-Wei

AU - Yang, Huanming

AU - Wang, Jian

AU - Wang, Jun

AU - Zhang, Xuan

AU - Madsen, Lise

AU - Brix, Susanne

AU - Ning, Guang

AU - Xu, Xun

AU - Liu, Xin

AU - Hou, Yong

AU - Jia, Huijue

AU - He, Kunlun

AU - Kristiansen, Karsten

PY - 2017/10/10

Y1 - 2017/10/10

N2 - The gut microbiota has been linked to cardiovascular diseases. However, the composition and functional capacity of the gut microbiome in relation to cardiovascular diseases have not been systematically examined. Here, we perform a metagenome-wide association study on stools from 218 individuals with atherosclerotic cardiovascular disease (ACVD) and 187 healthy controls. The ACVD gut microbiome deviates from the healthy status by increased abundance of Enterobacteriaceae and Streptococcus spp. and, functionally, in the potential for metabolism or transport of several molecules important for cardiovascular health. Although drug treatment represents a confounding factor, ACVD status, and not current drug use, is the major distinguishing feature in this cohort. We identify common themes by comparison with gut microbiome data associated with other cardiometabolic diseases (obesity and type 2 diabetes), with liver cirrhosis, and rheumatoid arthritis. Our data represent a comprehensive resource for further investigations on the role of the gut microbiome in promoting or preventing ACVD as well as other related diseases.

AB - The gut microbiota has been linked to cardiovascular diseases. However, the composition and functional capacity of the gut microbiome in relation to cardiovascular diseases have not been systematically examined. Here, we perform a metagenome-wide association study on stools from 218 individuals with atherosclerotic cardiovascular disease (ACVD) and 187 healthy controls. The ACVD gut microbiome deviates from the healthy status by increased abundance of Enterobacteriaceae and Streptococcus spp. and, functionally, in the potential for metabolism or transport of several molecules important for cardiovascular health. Although drug treatment represents a confounding factor, ACVD status, and not current drug use, is the major distinguishing feature in this cohort. We identify common themes by comparison with gut microbiome data associated with other cardiometabolic diseases (obesity and type 2 diabetes), with liver cirrhosis, and rheumatoid arthritis. Our data represent a comprehensive resource for further investigations on the role of the gut microbiome in promoting or preventing ACVD as well as other related diseases.

UR - http://www.scopus.com/inward/record.url?scp=85031012310&partnerID=8YFLogxK

U2 - 10.1038/s41467-017-00900-1

DO - 10.1038/s41467-017-00900-1

M3 - Journal article

C2 - 29018189

AN - SCOPUS:85031012310

SN - 2041-1723

VL - 8

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 845

ER -

The gut microbiome in atherosclerotic cardiovascular disease

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this